Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma

Cancer Research

Volumn 73, Issue 1, 2013, Pages 195-204

  Cazes, Alex ^a,b   Louis Brennetot, Caroline ^a,b   Mazot, Pierre ^c,d,e   Dingli, Florent ^f   Lombard, Béraǹre ^f   Boeva, Valentina ^b,g,h   Daveau, Romain ^a,b   Cappo, Julie ^a,b   Combaret, Valérie ⁱ   Schleiermacher, Gudrun ^a,b   Jouannet, Stéphanie ^a,b   Ferrand, Sandrine ^b   Pierron, Gaëlle ^b   Barillot, Emmanuel ^b,g,h   Loew, Damarys ^f   Vigny, Marc ^c,d,e   Delattre, Olivier ^a,b   Janoueix Lerosey, Isabelle ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e INSTITUT DU FER À MOULIN   (France)

^f Laboratoire de Sectrométrie de Masse Protéomique   (France)

^g INSERM U900   (France)

^h PSL RESEARCH UNIVERSITY   (France)

ⁱ CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PROTEIN TYROSINE KINASE;

ALK GENE; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; STABLE EXPRESSION;

CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; GENE REARRANGEMENT; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION, FLUORESCENCE; NEUROBLASTOMA; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84871990215     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1242     Document Type: Article

References (31)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010;29: 1566-79.
3. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362:2202-11.
4. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23.
5. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009;420: 345-61.
6. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008;416:153-9.
7. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4.
8. de Pontual L, Kettaneh D, Gordon CT, Oufadem M, Boddaert N, Lees M, et al. Germline gain-of-function mutations of ALK disrupt central nervous system development. Human Mutation 2011;32:272-6.
9. George RE, Sanda T, Hanna M, Frohling S, Luther W II, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-8.
10. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70.
11. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
12. De Brouwer S, De Preter K,KumpsC, Zabrocki P, Porcu M, Westerhout EM, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010;16:4353-62.
13. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009;69: 7338-46.
14. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
15. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-33.
16. Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009;9:331-56.
17. Schleiermacher G, Bourdeaut F, Combaret V, Picrron G, Raynal V, Aurias A, et al. Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene 2005;24:3377-84.
18. Schleiermacher G, Janoueix-Lerosey I, Combaret V, Derre J, Couturier J, Aurias A, et al. Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet 2003;141:32-42.
19. Schleiermacher G, Raynal V, Janoueix-Lerosey I, Combaret V, Aurias A, Delattre O. Variety and complexity of chromosome 17 translocations in neuroblastoma. Genes Chromosomes Cancer 2004;39:143- 50.
20. Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J, et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005;280:26039-48.
21. Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V, et al. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene 2011;30:2017-25.
22. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389-95.
23. Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg RM, Abrahamsson J, et al. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 2008;9:353.
24. Fix A, Lucchesi C, Ribeiro A, Lequin D, Pierron G, Schleiermacher G, et al. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes Cancer 2008;47:819- 34.
25. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214-20.
26. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
27. Okubo J, Takita J, Chen Y, Oki K, Nishimura R, Kato M, et al. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. Oncogene 2012 Jan 16. [Epub ahead of print].
28. Clarke ID, Dirks PB. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene 2003;22:722-33.
29. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992;89:4309-13.
30. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55: 5536-9.
31. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 2010;24:2205-18.